And (c) the amount of Zantrene required for inhibition of FTO is likely to be significantly less than the historical dosing of Zantrene when it was being used as a chemotherapeutic.
Thankfully these factors are all in our favour, however they are not a guarantee that everything goes smoothly. Daniel has previously mentioned it as one of the risks that RAC faces.
And (c) the amount of Zantrene required for inhibition of FTO is...
-
- There are more pages in this discussion • 870 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.095(5.44%) |
Mkt cap ! $281.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $285.9K | 170.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16759 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 12047 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |